Donor Chimerism
Donor Chimerism - Related Videos
21:01
Generating Chimeric Zebrafish Embryos by Transplantation
0 Views •
Cited by 61 •
2009
A step-by-step guide to generating targeted chimeric zebrafish embryos by transplantation at the blastula or gastrula stage.
07:17
Single Port Donor Nephrectomy
0 Views •
Cited by 5 •
2011
Single port laparoscopic surgery is changing the standard of care in surgical care like nothing since the laparoscopic technique was introduced 20 years ago. We present out technique of single port donor nephrectomy using the Gelpoint device. We have successfully performed this surgery in 100 patients.
09:17
Minimally Invasive Muscle Embedding (MIME) - A Novel Experimental Technique to Facilitate Donor-Cell-Mediated Myogenesis
0 Views •
Cited by 3 •
2017
We describe a novel experimental technique that we call Minimally Invasive Muscle Embedding (MIME), which is based on the evidence that skeletal muscle tissue contains viable myogenic cells that can facilitate donor-cell-mediated myogenesis when implanted into a host muscle.
12:13
Ex Situ Normothermic Machine Perfusion of Donor Livers
0 Views •
Cited by 21 •
2015
Here we present a protocol describing oxygenated ex situ machine perfusion of donor liver grafts. This article contains a step by step protocol to procure and prepare the liver graft for machine perfusion, prepare the perfusion fluid, prime the perfusion machine and perform oxygenated normothermic machine perfusion of the liver graft.
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
0 Views •
Cited by 2 •
2017
Quantification of donor-derived cells is required to monitor engraftment after stem cell transplantation in patients with hemoglobinopathies. A combination of flow cytometry-based cell sorting, colony formation assay, and subsequent analysis of short tandem repeats may be used to assess the proliferation and differentiation of progenitors in the erythroid compartment.
FAQs
The analysis compares genetic markers found in donor and recipient cells, commonly using short tandem repeat analysis. These markers provide a way to identify which cells originate from each individual within the transplant recipient. The resulting comparison supports classification of the cellular composition as complete donor chimerism or mixed chimerism and helps evaluate the extent of engraftment.
Complete donor chimerism indicates that the assessed cell population is donor-derived, whereas mixed chimerism indicates that both donor-derived and recipient-derived cells remain detectable. This distinction provides information about how extensively the recipient’s blood-forming and immune cellular systems have been replaced. Interpreting the pattern over time can add clinical context beyond a single measurement.
Repeated measurements show whether donor-cell levels remain stable, increase, or decline after transplantation. A declining donor-cell proportion may signal relapse or graft failure, making the trend clinically important. Serial testing therefore helps clinicians monitor graft function and recognize changes that may require closer evaluation or a treatment-related response.
The donor-cell proportion offers an indirect view of immune system replacement following allogeneic hematopoietic stem cell transplantation. Higher representation of donor-derived cells reflects greater replacement of recipient cellular populations, while persistent recipient cells indicate mixed chimerism. This information helps connect engraftment status with the broader process of immune reconstitution after transplantation.
The workflow centers on comparing genetic markers from donor and recipient cells. Short tandem repeat analysis can distinguish the genetic contributions of these two sources, allowing the laboratory to estimate the donor-derived proportion in the recipient. Clinicians can then compare the result with earlier measurements to assess engraftment, graft function, and changing cellular patterns.
A reduction in donor-cell levels can raise concern for relapse or graft failure and may prompt clinicians to reassess graft function. Depending on the clinical situation, the findings can help guide interventions such as adjusting immunosuppression or administering donor lymphocyte infusions. The test therefore contributes to management decisions rather than serving only as a descriptive laboratory measurement.
In research, donor-cell measurements support investigations of transplant outcomes and immune reconstitution. Serial results can be examined alongside the course of engraftment and changes in donor and recipient cell populations. This helps researchers study how cellular replacement develops after allogeneic transplantation and how chimerism patterns relate to graft function and longer-term transplant observations.